M&A Deal Summary

Eagle Pharmaceuticals Acquires Acacia Pharma

On March 28, 2022, Eagle Pharmaceuticals acquired life science company Acacia Pharma for 95M USD

Acquisition Highlights
  • This is Eagle Pharmaceuticals’ 2nd transaction in the Life Science sector.
  • This is Eagle Pharmaceuticals’ largest (disclosed) transaction.
  • This is Eagle Pharmaceuticals’ 1st transaction in the United Kingdom.

M&A Deal Summary
Date 2022-03-28
Target Acacia Pharma
Sector Life Science
Buyer(s) Eagle Pharmaceuticals
Deal Type Going Private
Deal Value 95M USD
Advisor(s) Greenhill & Co., Inc.
Jefferies (Financial)
Sullivan & Cromwell
Eubelius (Legal)

Target

Acacia Pharma

Cambridge, United Kingdom
Acacia Pharma is a pharmaceutical company specializing in the development of drugs for cancer supportive care. The growth in the cancer supportive care market has been driven by the increasing incidence of cancer, the expansion of effective cancer therapies and the desire to improve both the effectiveness of treatment and the quality of life of cancer patients. Acacia Pharma was founded in 2007 and is based in Cambridge, United Kingdom.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Eagle Pharmaceuticals

Woodcliff Lake, New Jersey, United States
Category Company
Founded 2007
Sector Life Science
Employees134
Revenue 317M USD (2022)
DESCRIPTION

Eagle Pharmaceuticals is a pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle Pharmaceuticals was founded in 2007 and is based in Woodcliff Lake, New Jersey.

DEAL STATS #
Overall 2 of 3
Sector (Life Science) 2 of 3
Type (Going Private) 1 of 1
Country (United Kingdom) 1 of 1
Year (2022) 1 of 2
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-11-11 Arsia Therapeutics

Waltham, Massachusetts, United States

Arsia Therapeutics, Inc. is a biopharmaceutical company based on a platform technology for protein formulation. Arsia produces high-concentration, low-viscosity drug products, enabling biologics that would otherwise be dosed by intravenous infusion to be administered by subcutaneous injection, or delivered by autoinjector pen or patch pump.

Buy $78M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-08-09 Enalare Therapeutics

Princeton, New Jersey, United States

Enalare Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening acute respiratory and critical care conditions, including community drug overdose, postoperative respiratory depression, and apnea of prematurity. Enalare Therapeutics is based in Princeton, New Jersey.

Buy -
Mergr

Product

Company

Legal